What is the 13F Pro Quality Score for AMPH?

13F Pro ranks Amphastar Pharmaceuticals, Inc. (AMPH) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View AMPH's current score at https://13fpro.ai/research/AMPH (free sign-up required for the full ranking).

Which hedge funds own the most AMPH stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of AMPH include BlackRock,, DIMENSIONAL FUND ADVISORS, STATE STREET. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/AMPH as soon as new 13F filings post.

Where does 13F Pro source AMPH data?

All Amphastar Pharmaceuticals, Inc. fundamentals and ownership data come directly from SEC EDGAR. Amphastar Pharmaceuticals, Inc. files with the SEC under CIK 1297184. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is AMPH in?

Amphastar Pharmaceuticals, Inc. (AMPH) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is AMPH research updated on 13F Pro?

AMPH's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Amphastar Pharmaceuticals, Inc.(AMPH)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1297184 AMPH stock profile & AI dashboard →

13F Pro Quality Score

55.0/100

Rank #1,185 of 2,879 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

52.4/100

Profitability

58.7/100

Balance Sheet

69.8/100

Earnings Quality

15.0/100

Free Cash Flow

77.0/100

Institutional Flow

42.2/100

Revenue Scale

42.7/100

Dilution Risk

29.9/100

AMPH Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Amphastar Pharmaceuticals, Inc. (AMPH), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AMPH at 55.0/100 on a 32-signal composite quality model, placing it at rank #1,185 of 2,879 stocks — the top half of the AI-ranked universe. AMPH scores in the top quartile across free cash flow (77.0). Areas of concern include earnings quality (15.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 29.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Amphastar Pharmaceuticals, Inc. reports quarterly revenue of $171.2M, net income of $6.4M, free cash flow of $38.3M. Top institutional holders of AMPH by reported 13-F value include BlackRock,, DIMENSIONAL FUND ADVISORS, STATE STREET, based on the most recent SEC filings. AMPH trades on the Nasdaq exchange and files with the SEC under CIK 1297184. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AMPH daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Amphastar Pharmaceuticals, Inc. directly from SEC EDGAR. Amphastar Pharmaceuticals, Inc.'s 13F Pro composite quality score has ranged between 8 and 81 since 2021, currently 55.0 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about Amphastar Pharmaceuticals, Inc.

Quirks, history, and lore behind AMPH — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. specialty pharmaceutical company · listed on Nasdaq · headquartered in Southern California · focused on injectable and inhalation drugs.
2
The Numbers
Annual revenue in the range of roughly $600–700 million — small-cap territory, but punching above its weight in a handful of high-demand drug categories.
3
The History
Founded in the 1990s by a team with deep roots in the generic injectables business, it went public on Nasdaq and built its reputation supplying drugs that hospitals and emergency rooms actually depend on.
4
The Secret
It manufactures many of its products at its own facilities in California and China, giving it tighter control over supply than most generics rivals — a real edge during drug shortage crises.
5
The Lore
Its naloxone (the opioid overdose reversal drug) and epinephrine products have quietly made it a behind-the-scenes hero of U.S. emergency medicine, even if nobody at the ER knows its name.
6
The Giveaway
A specialty pharma maker based in Rancho Cucamonga whose ticker is AMPH — fittingly, almost like the prefix on the drug that keeps people breathing.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$171.2M

Net Income

Q1 2026

$6.4M

Free Cash Flow

Q1 2026

$38.3M

D/E Ratio

Q1 2026

0.79

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-1.7% YoY

$719.9MFY 2025

FY22 $499.0MFY23 $644.4MFY24 $732.0MFY25 $719.9M

Net Income

-38.5% YoY

$98.1MFY 2025

FY22 $91.4MFY23 $137.5MFY24 $159.5MFY25 $98.1M

Operating Income

-31.7% YoY

$140.4MFY 2025

FY22 $107.5MFY23 $197.0MFY24 $205.4MFY25 $140.4M

EPS (Diluted)

-33.7% YoY

$2.03FY 2025

FY22 $1.74FY23 $2.60FY24 $3.06FY25 $2.03

Total Assets

+3.3% YoY

$1.63BFY 2025

FY22 $742.0MFY23 $1.51BFY24 $1.58BFY25 $1.63B

Total Debt

+1.2% YoY

$621.3MFY 2025

FY22 $79.7MFY23 $603.6MFY24 $613.8MFY25 $621.3M

Op. Cash Flow

-26.8% YoY

$156.1MFY 2025

FY22 $89.2MFY23 $183.5MFY24 $213.4MFY25 $156.1M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$719.9M -1.7%	$732.0M +13.6%	$644.4M +29.1%	$499.0M +14.0%	$437.8M +25.1%	$349.8M
Net Income	$98.1M -38.5%	$159.5M +16.0%	$137.5M +50.5%	$91.4M +47.1%	$62.1M +4327.4%	$1.4M
Operating Income	$140.4M -31.7%	$205.4M +4.3%	$197.0M +83.2%	$107.5M +53.8%	$69.9M +538.0%	$11.0M
EPS (Diluted)	$2.03 -33.7%	$3.06 +17.7%	$2.60 +49.4%	$1.74 +39.2%	$1.25 +4066.7%	$0.03
Total Assets	$1.63B +3.3%	$1.58B +4.3%	$1.51B +103.9%	$742.0M +10.5%	$671.5M +6.4%	$631.2M
Total Debt	$621.3M +1.2%	$613.8M +1.7%	$603.6M +657.5%	$79.7M -0.9%	$80.4M +38.2%	$58.2M
Operating Cash Flow	$156.1M -26.8%	$213.4M +16.3%	$183.5M +105.8%	$89.2M -9.0%	$98.0M +71.1%	$57.3M

AI Insight: AMPH Financial Trends

Operating income collapsed to $14M in Q1 2026 — the lowest in the eight-quarter window — as net income fell 76% year-over-year from $25M to $6M.

• Operating income deteriorated sharply from $55M in Q2 2024 to $14M in Q1 2026, compressing implied op margin from ~30% to ~8%.

• Net income dropped from $38–40M range in Q2–Q3 2024 to just $6M in Q1 2026, a multi-quarter downtrend with no recovery.

• Revenue has oscillated between $171M and $192M across eight quarters, showing no meaningful growth trend.

• Total debt crept from $587M in Q2 2024 to $621M in Q4 2025, though Q1 2026 saw a slight reduction to $611M.

⚠ Operating CF of $48M in Q1 2026 meaningfully exceeds net income of $6M — monitor whether non-cash charges explain widening gap.

⚠ Operating income has fallen four consecutive quarters to $14M; any further compression risks inability to service $611M debt load.

⚠ Revenue held flat at $171M in Q1 2026 year-over-year — watch whether pricing pressure or volume loss is driving margin erosion.

AI Insight: AMPH Ratio Trends

AMPH's Q1 2026 operating margin collapsed to 8.0%, the lowest in the visible dataset, signaling a sharp and accelerating profitability deterioration.

• Operating margin fell from 30.3% in Q2 2024 to just 8.0% in Q1 2026 — a 22-percentage-point compression over seven quarters.

• ROIC dropped from a peak of 38.2% in Q3 2024 to 8.9% in Q1 2026, erasing more than three-quarters of capital return efficiency.

• Net profit margin fell to 3.8% in Q1 2026, down from 21.1% in Q3 2024, the steepest single-metric deterioration in the dataset.

• TTM figures (16.2% OpMargin, 19.1% ROIC) cushion the optics but still trail the Q2–Q3 2024 peak meaningfully.

⚠ Q1 2026 ROA of 1.6% is the lowest observed — monitor whether Q2 2026 shows stabilization or continued asset productivity erosion.

⚠ The partial Q4 2025 rebound (OpMargin 19.4%) reversed sharply in Q1 2026 — assess whether this reflects structural revenue loss or one-off cost items.

⚠ D/E data is absent throughout; leverage context is missing and critical given the magnitude of margin compression.

Get alerted when AMPH's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Amphastar Pharmaceuticals, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of AMPH

BlackRock, Inc.
$106.2M5,421,343 sh
DIMENSIONAL FUND ADVISORS LP
$39.7M2,027,947 sh
STATE STREET CORP
$31.5M1,607,515 sh
VANGUARD CAPITAL MANAGEMENT LLC
$30.2M1,543,655 sh
TD ASSET MANAGEMENT INC
$30.2M1,541,044 sh
FULLER & THALER ASSET MANAGEMENT, INC.
$27.3M1,395,139 sh
MARSHALL WACE, LLP
$20.1M1,025,640 sh
AMERICAN CENTURY COMPANIES INC
$19.9M1,017,538 sh
GEODE CAPITAL MANAGEMENT, LLC
$19.1M976,650 sh
Boston Trust Walden Corp
$18.5M944,789 sh

Fund	Value	Shares
BlackRock, Inc.	$106.2M	5,421,343
DIMENSIONAL FUND ADVISORS LP	$39.7M	2,027,947
STATE STREET CORP	$31.5M	1,607,515
VANGUARD CAPITAL MANAGEMENT LLC	$30.2M	1,543,655
TD ASSET MANAGEMENT INC	$30.2M	1,541,044
FULLER & THALER ASSET MANAGEMENT, INC.	$27.3M	1,395,139
MARSHALL WACE, LLP	$20.1M	1,025,640
AMERICAN CENTURY COMPANIES INC	$19.9M	1,017,538
GEODE CAPITAL MANAGEMENT, LLC	$19.1M	976,650
Boston Trust Walden Corp	$18.5M	944,789

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put AMPH on your watchlist

Track score changes the day Amphastar Pharmaceuticals, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is AMPH a good stock to buy?

13F Pro's AI-powered analysis of Amphastar Pharmaceuticals, Inc. (AMPH) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AMPH are available on the AMPH stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own AMPH?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AMPH. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Amphastar Pharmaceuticals, Inc.'s investment landscape.